Schwab Charles Investment Management Inc. Reduces Stake in Becton, Dickinson and Company (NYSE:BDX)

Schwab Charles Investment Management Inc. cut its position in Becton, Dickinson and Company (NYSE:BDX) by 5.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 987,230 shares of the medical instruments supplier’s stock after selling 55,545 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Becton, Dickinson and were worth $181,098,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. Crestwood Advisors Group LLC purchased a new position in Becton, Dickinson and during the first quarter worth approximately $101,000. North Star Investment Management Corp. increased its position in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares in the last quarter. Parkside Financial Bank & Trust increased its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares in the last quarter. Financial Architects Inc increased its position in Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares in the last quarter. Finally, QCI Asset Management Inc. NY increased its position in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) traded down 0.02% during midday trading on Tuesday, hitting $197.80. 174,686 shares of the stock traded hands. The company has a market capitalization of $42.19 billion, a PE ratio of 32.85 and a beta of 1.05. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm’s 50 day moving average price is $197.67 and its 200 day moving average price is $186.53.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s revenue was down 5.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.35 EPS. Analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s payout ratio is presently 83.43%.

COPYRIGHT VIOLATION WARNING: “Schwab Charles Investment Management Inc. Reduces Stake in Becton, Dickinson and Company (NYSE:BDX)” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/08/08/schwab-charles-investment-management-inc-reduces-stake-in-becton-dickinson-and-company-nysebdx.html.

Several equities analysts have commented on the company. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, July 17th. Royal Bank Of Canada reiterated a “hold” rating and set a $177.00 price target on shares of Becton, Dickinson and in a report on Thursday, April 13th. Finally, Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price target for the company from $186.00 to $200.00 in a report on Monday, April 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $194.69.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply